Bispecific antigen binding molecules that bind leptin receptor and/or GP130, and methods of use thereof
AssigneeRegeneron Pharmaceuticals, Inc.
InventorsJesper Gromada, Panayiotis Stevis, Judith Altarejos
Life of this patent
Estimating the term…
Loading patent…
AssigneeRegeneron Pharmaceuticals, Inc.
InventorsJesper Gromada, Panayiotis Stevis, Judith Altarejos
Estimating the term…
The present invention relates to antigen-binding molecules, including bispecific antigen-binding molecules that bind human GP130 and/or human leptin receptor (LEPR), and the use of such antigen-binding molecules for the treatment of conditions and disorders related to leptin deficiency or leptin resistance. The bispecific antigen-binding molecules of the present invention can be, e.g., bispecific antibodies comprising a first antigen-binding domain that specifically binds human GP130 and a second antigen-binding domain that specifically binds human LEPR. The bispecific antigen-binding molecules of the present invention are useful in therapeutic applications where induced leptin and/or LEPR-mediated signaling would be beneficial, e.g., in the treatment of obesity, lipodystrophies and other diseases and disorders associated with or caused by leptin deficiency or leptin resistance.
A bispecific antibody or antigen-binding fragment thereof, comprising:
A bispecific antibody or antigen-binding fragment thereof which is a product of a method comprising:
Dependencies are inferred from the claim text.